Skip to main content
. 2019 Feb 22;316(5):H1027–H1038. doi: 10.1152/ajpheart.00697.2018

Table 1.

Primers used for real-time PCR

Primer Sequence
Tlr3-forward 5′-CCAGAAGAATCTAATCAAATTAGATTTGTC-3′
Tlr3-reverse 5′-TTTTGCTAAGAGCAGTTCTTGGAG-3′
Tlr4-forward 5′-GGCAACTTGGACCTGAGGAG-3′
Tlr4-reverse 5′-CATGGGCTCTCGGTCCATAG-3′
AT1R-forward 5′-GCTGGCATTTTGTCTGGATAAC-3′
AT1R -reverse 5′-GCTTTTCTGGGTTGAGTTGG-3′
Mmp9-forward 5′-GAAGGCAAACCCTGTGTGTT-3′
Mmp9-reverse 5′-AGAGTACTGCTTGCCCAGGA-3′
Nox4-forward 5′-CTCTACTGGATGACTGGAAACC-3′
Nox4-reverse 5′-AGTCAGGTCTGTTTTCTTGCC-3′
Nppa-forward 5′-GTCTTGGCCTTTTGGCTTC-3′
Nppa-reverse 5′-TTCCTCAGTCTGCTCACTC-3′
Tnf-forward 5′-TGCCTATGTCTCAGCCTCTTC-3′
Tnf-reverse 5′-GAGGCCATTTGGGAACTTCT-3′
Tgfb2-forward 5′-GCTAATGTTGTTGCCCTCCT-3′
Tgfb2-reverse 5′-GCAGCAATTATCCTGCACATT-3′
Gapdh-forward 5′-CATTTCCTGGTATGACAATGAATACG-3′
Gapdh-reverse 5′-TCCAGGGTTTCTTACTCCTTGGA-3′

AT1R, angiotensin II receptor type 1; Mmp9, matrix metalloprotease 9; Nppa, atrial natriuretic peptide; Nox4, NADPH-oxidase 4; Tgfb2, transforming growth factor beta 2; Tlr3, Toll-like receptor 3; Tlr4, Toll-like receptor 4; Tnf, tumor necrosis factor-alpha.

HHS Vulnerability Disclosure